Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Epi Jaspine B SCHEMBL17356380 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1 | |
| SCHEMBL7125070 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1 | |
| SCHEMBL7129859 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1 | |
| SCHEMBL6276277 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1 | |
| 2-Epi Jaspine B SCHEMBL7125067 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1 | |
| SCHEMBL7596269 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1 | |
| 2-Epi Jaspine B SCHEMBL17356379 | 1.00 | SPHK2 (1.00) | SPHK2SPHK1 | |
| SCHEMBL17350826 | 0.85 | SPHK1 (0.73) | SPHK2SPHK1 | |
| SCHEMBL22576609 | 0.85 | SPHK1 (0.73) | SPHK2SPHK1 | |
| SCHEMBL11117820 | 0.81 | SPHK2 (0.69) | SPHK2SPHK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 117 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107011292-B | Jaspine B, 3-epi-Jaspine B nitrogen are for analog, preparation method and application | 郑州大学 | 2019-06-07 | — | — | CN | claimed |
| CN-105693660-B | Jaspine B, 3 epi Jaspine B oxo analogs, its preparation method and application | 郑州大学 | 2018-04-13 | — | — | CN | claimed |
| CN-107011292-A | Jaspine B, 3 epi Jaspine B nitrogen are for analog, its preparation method and application | 郑州大学 | 2017-08-04 | — | — | CN | claimed |
| CN-103304549-B | Jaspine B, 3-epi Jaspine B triazole class derivative, its preparation method and application thereof | ZHENGZHOU UNIVERSITY (CN) | 2015-09-02 | — | — | CN | claimed |
| CN-103601706-B | Method for synthesizing natural product Jaspine B isomer | UNIV JIANGXI NORMAL SCI & TECH | 2015-07-01 | — | — | CN | claimed |
| CN-102382081-B | Synthetic method of key intermediates of natural products jaspine B and 3-epi jaspine B possessing antineoplastic activity | UNIV ZHENGZHOU | 2014-04-16 | — | — | CN | claimed |
| CN-103601706-A | Method for synthesizing natural product Jaspine B isomer | UNIV JIANGXI NORMAL SCI & TECH | 2014-02-26 | — | — | CN | claimed |
| US-8609718-B2 | Pharmaceutical composition used in treatment of hyperproliferative skin conditions and malignant melanomas comprising pachastrissamine as active ingredient | CATHOLIC UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION (KR) | 2013-12-17 | — | — | US | claimed |
| CN-103304549-A | Jaspine B, 3-epi Jaspine B triazole derivative as well as preparation method and application thereof | UNIV ZHENGZHOU | 2013-09-18 | — | — | CN | claimed |
| US-20120071424-A1 | PHARMACEUTICAL COMPOSITION USED IN PROPHYLAXIS OR TREATMENT OF HYPERPROLIFERATIVE SKIN CONDITIONS AND MALIGNANT MELANOMAS COMPRISING PACHASTRISSAMINE AS ACTIVE INGREDIENT | CATHOLIC UNIVERSITY INDUSTRY ACADEMY COOPERATION FOUNDATION (KR) | 2012-03-22 | — | — | US | claimed |
| CN-102382081-A | Synthetic method of key intermediates of natural products jaspine B and 3-epi jaspine B possessing antineoplastic activity | UNIV ZHENGZHOU | 2012-03-21 | — | — | CN | claimed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025016469-A1 | ALKOXY THIOPHENE ACYL ARYLAMINE COMPOUNDS AND USE THEREOF | 复旦大学 | 2025-01-23 | — | — | WO | disclosed |
| CN-119320385-A | Alkoxy thiophene carboxamide compounds and application thereof | 复旦大学 | 2025-01-17 | — | — | CN | disclosed |
| WO-2011012715-A1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2011-02-03 | — | — | WO | disclosed |
| WO-2010107251-A3 | PHARMACEUTICAL COMPOSITION USED IN PROPHYLAXIS OR TREATMENT OF HYPERPROLIFERATIVE SKIN CONDITIONS AND MALIGNANT MELANOMAS COMPRISING PACHASTRISSAMINE AS ACTIVE INGREDIENT | 가톨릭대학교 산학협력단 (KR) | 2011-01-06 | — | — | WO | disclosed |
| WO-2010107251-A3 | PHARMACEUTICAL COMPOSITION USED IN PROPHYLAXIS OR TREATMENT OF HYPERPROLIFERATIVE SKIN CONDITIONS AND MALIGNANT MELANOMAS COMPRISING PACHASTRISSAMINE AS ACTIVE INGREDIENT | 가톨릭대학교 산학협력단 (KR) | 2011-01-06 | — | — | WO | disclosed |
| WO-2010107251-A2 | PHARMACEUTICAL COMPOSITION USED IN PROPHYLAXIS OR TREATMENT OF HYPERPROLIFERATIVE SKIN CONDITIONS AND MALIGNANT MELANOMAS COMPRISING PACHASTRISSAMINE AS ACTIVE INGREDIENT | 가톨릭대학교 산학협력단 (KR) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010107251-A2 | PHARMACEUTICAL COMPOSITION USED IN PROPHYLAXIS OR TREATMENT OF HYPERPROLIFERATIVE SKIN CONDITIONS AND MALIGNANT MELANOMAS COMPRISING PACHASTRISSAMINE AS ACTIVE INGREDIENT | 가톨릭대학교 산학협력단 (KR) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071424-A1 | PHARMACEUTICAL COMPOSITION USED IN PROPHYLAXIS OR TREATMENT OF HYPERPROLIFERATIVE SKIN CONDITIONS AND MALIGNANT MELANOMAS COMPRISING PACHASTRISSAMINE AS ACTIVE INGREDIENT | FOXO3, FOXM1, NFATC1 | SPHK2 98/4885SPHK1 104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.